MDXG
MiMedx Group Inc
4.70$
-1.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +26.5% | -7.3% | +3.8% | +6.0% | +8.2% | +2.5% | +7.7% | +9.6% | +7.4% | -9.9% | -9.0% | |
| – | +6.3% | -15.5% | +10.9% | +11.8% | +11.5% | +4.3% | +10.4% | +15.0% | +9.2% | -13.4% | -14.5% | |
| – | +1.0% | -40.9% | +42.4% | +28.6% | +17.6% | +1.9% | +11.7% | +19.5% | +16.9% | -3.8% | -15.0% | |
| – | +1.0% | -40.9% | +42.4% | +28.6% | +17.6% | +1.9% | +11.7% | +19.5% | +16.9% | -3.8% | -15.0% | |
| – | +9.9% | +5.8% | -7.4% | +2.3% | +3.3% | +11.6% | +11.1% | +12.9% | -3.2% | -39.2% | -10.3% | |
| – | +10.2% | +16.3% | +2.5% | -3.2% | -1.8% | +1.1% | +3.4% | +6.5% | -4.4% | +3.5% | -20.2% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -2.6% | +138.7% | -4.0% | -7.0% | +3.8% | -4.9% | +8.7% | -7.3% | +27.0% | -7.2% | -8.0% | |
| – | -48.7% | -31.5% | -5.8% | +1.2% | +12.6% | -4.5% | +10.1% | +7.5% | +7.6% | -23.7% | -1.1% | |
| – | +5.5% | -8.2% | -5.2% | +4.8% | +8.7% | -6.5% | +18.0% | +14.7% | +11.4% | -30.7% | -13.6% | |
| – | – | -35.4% | +0.0% | +0.0% | +130.7% | -51.2% | +11.1% | +10.0% | +105.1% | -46.8% | +0.0% | |
| – | -1.3% | +7.2% | -21.6% | -8.9% | +7.0% | +19.7% | -4.2% | +34.3% | +27.3% | -21.1% | -27.7% | |
| – | -1.8% | -61.6% | -1.1% | -1.3% | -1.0% | -1.7% | -1.8% | -2.2% | -2.2% | -2.3% | -2.4% | |
| – | +10,630.6% | +9.1% | +7.9% | +7.7% | +6.7% | +5.0% | +6.8% | +10.3% | +7.4% | -5.3% | -11.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +24.1% | +1.3% | -0.8% | -0.4% | +0.5% | +0.4% | -0.2% | +0.3% | +0.0% | -0.9% | -0.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.